Femamed 2.5 by Deus Medicals

FEMAMED 2.5 (Letrozole) has a place with a gathering of medications called aromatase inhibitors. It is a hormonal (or "endocrine") bosom malignant growth treatment. Development of bosom malignant growth is much of the time invigorated by estrogens which are female sex chemicals. FEMAMED 2.5 diminishes how much estrogen by hindering a compound ("aromatase") associated with the creation of estrogens and in this manner might impede the development of bosom disease that needs estrogens to develop.